Takahiro Shinzato
Overview
Explore the profile of Takahiro Shinzato including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
186
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kinoshita Y, Yagisawa T, Sugihara T, Hara K, Takeshima S, Kubo T, et al.
Transpl Int
. 2020 Jul;
33(11):1417-1423.
PMID: 32654198
We retrospectively compared the post-transplantation graft survival and the donor's estimated glomerular filtration rates (eGFRs) following living donor kidney transplantations (LDKTs) involving medically complex living donors (MCLDs) (the elderly and...
12.
Nanmoku K, Kawabata N, Kinoshita Y, Shinzato T, Kubo T, Shimizu T, et al.
Clin Exp Nephrol
. 2019 Dec;
24(4):379-383.
PMID: 31875933
Background: Sarcopenia is prevalent in patients with chronic kidney disease and is associated with increased mortality; however, limited data are available on whether kidney transplantation can improve muscle wasting. Therefore,...
13.
Shimizu T, Kinoshita Y, Kubo T, Shinzato T, Nanmoku K, Yagisawa T
Int Urol Nephrol
. 2019 Oct;
51(11):2091-2092.
PMID: 31583580
No abstract available.
14.
Nanmoku K, Shinzato T, Kubo T, Shimizu T, Yagisawa T
Transplant Direct
. 2019 Jul;
5(7):e467.
PMID: 31334341
Background: Rituximab is used widely for desensitization in ABO-incompatible and donor-specific antibody-positive kidney transplantation. However, data about the effects of individual differences in rituximab-induced B-cell suppression on antibody-mediated rejection (AMR)...
15.
Nanmoku K, Shinzato T, Kubo T, Shimizu T, Yagisawa T
Transplant Proc
. 2019 Jul;
51(8):2602-2605.
PMID: 31324482
Background: Rabbit antithymocyte globulin (rATG) induction is associated with reduction in the occurrence of de novo donor-specific antibody (DSA) and antibody-mediated rejection (AMR). Therefore, rATG administration is considered as a...
16.
Nanmoku K, Shinzato T, Kubo T, Shimizu T, Yagisawa T
Transpl Infect Dis
. 2019 May;
21(4):e13116.
PMID: 31102475
Post-transplant lymphoproliferative disorder (PTLD) is a fatal complication of transplantation. There is no clear consensus on the treatment of PTLD. In most cases, the pathogenetic mechanism of PTLD involves the...
17.
Nanmoku K, Shinzato T, Kubo T, Shimizu T, Yagisawa T
Transplant Proc
. 2019 May;
51(5):1424-1427.
PMID: 31060742
Background: Calcineurin inhibitors (CNIs), which remain the most important immunosuppressants in kidney transplant recipients, are a major cause of renal dysfunction due to CNI-induced nephropathy. However, a safe and effective...
18.
Nanmoku K, Shinzato T, Kubo T, Shimizu T, Yagisawa T
Clin Nephrol
. 2019 Apr;
92(1):1-8.
PMID: 30990412
Background: Hypercalcemia and bone mineral density (BMD) loss are serious problems associated with post-transplant chronic kidney disease-mineral and bone disorder. The present study aimed to clarify the effects of denosumab...
19.
Fujiwara S, Ikeda T, Morita K, Shinzato T, Ishikawa N, Nakamura N, et al.
Am J Transplant
. 2019 Mar;
19(8):2374-2377.
PMID: 30916888
Patients who undergo kidney transplantation are at increased risk of cancer due to the long-term use of immunosuppressive treatment. Postrenal transplant cancers usually originate from recipient cells, but donor-related cancers...
20.
Shinzato T, Kubo T, Shimizu T, Nanmoku K, Yagisawa T
CEN Case Rep
. 2019 Jan;
8(2):101-105.
PMID: 30604247
Fibrosing cholestatic hepatitis (FCH) is a fatal disorder that presents as a progressive deterioration of liver function over a period of several weeks to several months. It is caused by...